Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Technologies
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developers of innovative devices, aiming to speed patient access while upholding the EU’s strict safety and performance standards.
Designation Criteria Target Real Clinical Advances
The most impactful element is the structured breakthrough designation for devices demonstrating a high degree of innovation together with either the potential to address unmet medical needs or the ability to deliver significant clinical benefit compared with current technologies. In the first phase (Ia), limited to class III and certain class IIb devices, EMA will select only five applications. Priority is given to cardiovascular devices and those for paediatric populations.
Selected manufacturers receive free, stage-specific expert panel advice covering pre-clinical evidence, clinical strategy, proposed investigations, and post-market follow-up. This early input is designed to strengthen clinical evaluation dossiers and reduce uncertainties during conformity assessment. Notified bodies can also submit targeted questions on clinical data requirements, with one of the five selected applications required to involve the manufacturer’s notified body.
Structured Application Process Built on Existing Guidance
Applications begin with a letter of interest submitted via EMA’s dedicated portal, selecting “Advice in scope of MDCG guidance 2025-9”. Full templates are submitted only after selection. The expert panels, supported by national competent authorities, assess innovation, unmet need, and comparative benefit using criteria set out in the MDCG Guidance on Breakthrough Devices published in December 2025.
The pilot runs in three phases until 2027. Phase Ia is restricted to the highest-risk categories with a narrow selection cap. Later phases will expand to additional device types, including in vitro diagnostics. This progressive approach extends the existing expert panel system into upstream development support and paves the way for a formal breakthrough framework under proposed revisions to the Medical Devices Regulation (MDR) and In Vitro Diagnostic Devices Regulation (IVDR).
Strategic Implications for Market Access and Reimbursement
Early expert feedback on clinical plans and post-market data should produce higher-quality evidence earlier, strengthening value propositions to HTA bodies and payers. Devices that secure designation may achieve faster uptake and more favourable reimbursement decisions, particularly in cardiovascular and paediatric fields. Manufacturers are encouraged to integrate economic evaluations and patient-reported outcomes into the clinical strategies reviewed by the expert panels. As the pilot evolves into a formal pathway, it promises greater predictability at both regulatory and payer levels, ultimately supporting faster, more sustainable patient access to transformative technologies.
